2Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle proliferation and migration in vitro and in vivo using local drug delivery[J] . Circulation, 1997, 96(2) :636-645.
3Fanggiday JC, Stella PR, Guyomi SH, et al. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions= the DEBIUT (drug eluting balloon in bifurcation Utrecht) registry[J]. Catheter Cardiovasc Interv, 2008,71(5) :629-635.
4Cremers B, Biedermann M, Mahnkopf D, et al. Comparison of two different paclitaxel-coated catheters in the porcine coronary restenosis model [ J] . Clin Res Cardiol, 2009, 98(5) :325-30.
5Scheller B. Opportunities and limitations of drug-coated balloons in interventional therapies [J]. Herz,2011,36(3) :232-239.
6Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymebased paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial [J]. JAMA, 2005, 294 (10) : 1215 -1223.
7Vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the Angioplasty versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial ( ARTIST ) [ J ]. Circulation,2002,105(5) :583-588.
8Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in- stent restenosis: a randomized controlled trial[J]. JAMA, 2005,293 (2) : 165-171.
9Seheller B, Hehrlein C, Bockseh W, et al. Treatment of coronary in-stent restenosis with a paclitaxel coated balloon catheter[J]. N Engl J Med,2006,355(20) :2113-2124.
10Scheller B, Hehrlein C, Bocksch W, et al. Two year follow- up after treatment of coronary in stent restenosis with a paclitaxel-coated balloon catheter[J]. Clin Res Cardiol,2008, 97(10) :773- 781.
